Enovis Corporation (NYSE:ENOV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Enovis Corporation (NYSE:ENOV) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $41.8571.

A number of brokerages recently weighed in on ENOV. UBS Group restated a “buy” rating and set a $51.00 price objective (up from $50.00) on shares of Enovis in a research note on Tuesday. BMO Capital Markets started coverage on shares of Enovis in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $29.00 price target for the company. Evercore set a $32.00 price target on shares of Enovis in a research note on Monday, July 6th. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, William Blair began coverage on shares of Enovis in a research note on Friday, April 17th. They set an “outperform” rating on the stock.

Insider Transactions at Enovis

In other news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders acquired 4,200 shares of company stock worth $92,084. Company insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Arax Advisory Partners bought a new position in Enovis during the fourth quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after acquiring an additional 707 shares during the period. GAMMA Investing LLC raised its position in Enovis by 353.5% in the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after acquiring an additional 1,446 shares in the last quarter. Danske Bank A S bought a new stake in Enovis in the third quarter worth about $64,000. Finally, iSAM Funds UK Ltd acquired a new stake in Enovis in the 3rd quarter valued at about $80,000. Institutional investors own 98.45% of the company’s stock.

Enovis Stock Performance

Shares of ENOV stock opened at $29.32 on Friday. Enovis has a 12-month low of $19.14 and a 12-month high of $34.28. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -1.47 and a beta of 1.39. The business has a 50 day simple moving average of $23.96 and a 200 day simple moving average of $23.78.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the previous year, the business earned $0.81 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts anticipate that Enovis will post 3.12 EPS for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.